N/A N=91 Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
Respiratory Syncytial Virus Infection
Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
Phase 3 N=36 The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia
Fibromyalgia
Primary: Change in Ratio of Choline/ Creatine (CHO/CR) in the Brain From Baseline to 3 Hrs Post-endotoxin Administration — -.0021; -.0058 ratio
N/A N=20 Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study
Influenza Virus Vaccine
Primary: Levels of Cytokine Interferon Gamma (IFN-gamma) Responses to Inactivated Influenza Vaccine — 1.3; 1.4; 1.3; 6.9 pg/mL
N/A N=190 Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
Common Cold
Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml
Phase 4 N=13 The Human Mucosal Immune Responses to Influenza Virus (SLVP026)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 3; 8 Participants
Phase 4 N=8 B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
Phase 4 N=91 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
N/A N=20 Immune Responses With Reduxium
Immune Tolerance · Viral Infection
Primary: Immune T Cell Subsets and Immunophenotype After 2 Weeks of Reduxium Intake — 60.53; 60; 59.29; 56.52 percentage of cells
N/A N=193 Immune Responses Induced by Different Licensed Influenza Vaccines
Immune Response
Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
Phase 4 N=18 Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 0; 17 Participants
Phase 1 N=89 Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants
Focus: Nutritional Requirements for Infants
Primary: Number of Antigen-presenting B Cells — 21.9; 22.8; 25.1 percentage of CD20+ B cells
N/A N=107 Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
Influenza
Primary: Determination of Immune Response to Vaccination. — 45 participants
Phase 2 N=46 Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
Healthy Volunteers
Primary: Virus Infection — 8; 18 Participants
N/A N=10 Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers
Hepatitis B
Primary: Number of Differentially Expressed Genes at p < 0.05 (Without Multiple Testing Correction). — 138; 138; 102; 81 number of genes at p<0.05
Phase 4 N=20 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 20 Participants
Phase 4 N=103 Immune and Hormone Response to Influenza Vaccine
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml
N/A N=48 Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Influenza · Vaccine Virus Shedding
Primary: Number of Participants Shedding Each Vaccine Virus Measured by qPCR of Nasosorption Samples — 31 participants
N/A N=28 The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus
RSV Infection
Primary: Number of Participants With Challenge-related Adverse Events — 0; 3 Participants
N/A N=15 γ-irradiated BCG to Train Innate Immunity
Innate Immune Response
Primary: Cytokine Production Measured by ELISA Compared to Baseline — 1.2 ratio
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
Phase 4 N=22 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 5; 5; 6; 3 Participants
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
N/A N=46 Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)
Infections, Clostridium Difficile
Primary: Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 14 — 2083.3; 3189.4; 32096.4 EU/mL — p=0.5746
Phase 4 N=51 Revealing Protective Immunity to Influenza Using Systems Immunology
Influenza
Primary: Quantification of Antibody Titers — 37.4; 24.6; 6.81 Antibody titer
Phase 2 N=38 Clinical Response to Rhinovirus Challenge
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
Phase 4 N=63 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011
Influenza
Primary: Number of Individual Twins Who Received Influenza Vaccine — 8; 10; 20; 12 Participants
N/A N=10 Effects of Surfactants on the Innate Immune System
Healthy
Primary: Normalized LL-37 Expression — 100 percentage of baseline
Early Phase 1 N=12 Ivermectin and Human Immunity
Ivermectin
Primary: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded. — 0; 0; 0; 0 Cytokines changed from t=0